北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第三临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial
作者: Zheng, Jin-Ping1; Wen, Fu-Qiang2; Bai, Chun-Xue3; Wan, Huan-Ying4; Kang, Jian5; Chen, Ping6; Yao, Wan-Zhen7; Ma, Li-Jun8; Li, Xia9; Raiteri, Luca10; Sardina, Marco10; Gao, Yi1; Wang, Bai-Song11; Zhong, Nan-Shan1; PANTHEON Study Grp
刊名: LANCET RESPIRATORY MEDICINE
发表日期: 2014-03-01
DOI: 10.1016/S2213-2600(13)70286-8
卷: 2, 期:3, 页:187-194
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Respiratory System
研究领域[WOS]: Respiratory System
关键词[WOS]: FLUTICASONE PROPIONATE ; CHINESE PATIENTS ; COPD ; EFFICACY ; SALMETEROL ; CARBOCISTEINE ; SAFETY ; 1-YEAR
英文摘要:

Background Increased oxidative stress and inflammation has a role in the pathogenesis of chronic obstructive pulmonary disease (COPD). Drugs with antioxidant and anti-inflammatory properties, such as N-acetylcysteine, might provide a useful therapeutic approach for COPD. We aimed to assess whether N-acetylcysteine could reduce the rate of exacerbations in patients with COPD.

Methods In our prospective, randomised, double-blind, placebo-controlled, parallel-group study, we enrolled patients aged 40-80 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity <0.7 and FEV1 of 30-70% of predicted) at 34 hospitals in China. We stratified patients according to use of inhaled corticosteroids (regular use or not) at baseline and randomly allocated them to receive N-acetylcysteine (one 600 mg tablet, twice daily) or matched placebo for 1 year. The primary endpoint was the annual exacerbation rate in patients who received at least one dose of study drug and had at least one assessment visit after randomisation. This study is registered with the Chinese Clinical Trials Registry, ChiCTR-TRC-09000460.

Findings Between June 25, 2009, and Dec 29, 2010, we screened 1297 patients, of whom 1006 were eligible for randomisation (504 to N-acetylcysteine and 502 to placebo). After 1 year, we noted 497 acute exacerbations in 482 patients in the N-acetylcysteine group who received at least one dose and had at least one assessment visit (1.16 exacerbations per patient-year) and 641 acute exacerbations in 482 patients in the placebo group (1.49 exacerbations per patient-year; risk ratio 0.78, 95% CI 0.67-0.90; p=0.0011). N-acetylcysteine was well tolerated: 146 (29%) of 495 patients who received at least one dose of N-acetylcysteine had adverse events (48 serious), as did 130 (26%) of 495 patients who received at least one dose of placebo (46 serious). The most common serious adverse event was acute exacerbation of COPD, occurring in 32 (6%) of 495 patients in the N-acetylcysteine group and 36 (7%) of 495 patients in the placebo group.

Interpretation Our findings show that in Chinese patients with moderate-to-severe COPD, long-term use of N-acetylcysteine 600 mg twice daily can prevent exacerbations, especially in disease of moderate severity. Future studies are needed to explore efficacy in patients with mild COPD (GOLD I).

语种: 英语
项目资助者: Hainan Zambon Pharmaceutical
WOS记录号: WOS:000336715100016
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/62158
Appears in Collections:北京大学第三临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 3, Beijing 100871, Peoples R China
2.Henan Prov Peoples Hosp, Zhengzhou, Peoples R China
3.Hainan Zambon Pharmaceut, Beijing, Peoples R China
4.Zambon, Innovat & Med Sci Dept, Milan, Italy
5.MedKey Med Tec Dev, Shanghai, Peoples R China
6.Shenyang PLA Gen Hosp, Shenyang, Peoples R China
7.Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis,Guangzhou Inst Resp Dis, Guangzhou, Guangdong, Peoples R China
8.Sichuan Univ, West China Hosp, Chengdu 610064, Peoples R China
9.Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China
10.China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China
11.Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Shanghai 200030, Peoples R China

Recommended Citation:
Zheng, Jin-Ping,Wen, Fu-Qiang,Bai, Chun-Xue,et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial[J]. LANCET RESPIRATORY MEDICINE,2014,2(3):187-194.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zheng, Jin-Ping]'s Articles
[Wen, Fu-Qiang]'s Articles
[Bai, Chun-Xue]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zheng, Jin-Ping]‘s Articles
[Wen, Fu-Qiang]‘s Articles
[Bai, Chun-Xue]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace